We have therefore demonstrated the potential relevance of 4T1, TUBO, and BALB-neuT tumors as appealing models with which to study the involvement of TENM4 in TNBC- and HER2-positive breast cancer’s initiation and progression, and the clinical impact of its immune-targeting. This evidence concerns the gene TENM4 and breast cancer.